NovaBridge Biosciences.
Research NovaBridge Biosciences. (NBP) on Bullrun: market cap USD 152.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNBP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 152.66M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 152.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 46.27M | -USD 20.60M | n/a | -0.21 | USD 210.63M | USD 3.07M | USD 230.94M |
| FY2024 | USD 0 | -USD 22.23M | -USD 52.72M | n/a | -0.12 | USD 68.26M | USD 3.88M | USD 201.16M |
| FY2023 | USD 632.00K | -USD 207.73M | -USD 183.96M | 617.1% | -1.09 | USD 291.51M | USD 4.22M | USD 242.58M |
| FY2022 | -USD 1.55M | -USD 371.05M | -USD 1.10B | 1856.1% | -1.96 | USD 342.92M | USD 18.96M | USD 417.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 152.66M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 459.22M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 69.28M | 1.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 156.98M | 2.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 347.35M | 6.1 | n/a | n/a |
| 2021 | 2021-12-31 | USD 3.79B | 69.7 | n/a | n/a |
About NovaBridge Biosciences.
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NovaBridge Biosciences.'s market cap?
NovaBridge Biosciences.'s market capitalization is USD 152.66M.
What does NovaBridge Biosciences. do?
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer.